吸烟在HPV阳性口咽癌AJCC第八版分期下的预后意义
结果显示≥10包年吸烟者5年OS更差,且吸烟与临床分期存在交互作用,低分期患者吸烟影响更大。
要点
- HPV阳性口咽癌中,≥10包年吸烟者5年OS显著低于<10包年者。
- 仅临床I期患者中,<10包年吸烟者5年OS显著优于≥10包年者。
- 调整AJCC第八版临床或病理分期后,≥10包年吸烟与死亡风险增加独立相关。
核心结论
- 吸烟是HPV阳性口咽鳞状细胞癌的不良预后因素,并与AJCC第八版临床分期存在交互作用。
- 在制定治疗方案和降强度试验时,应重视吸烟对HPV阳性疾病的影响。
主要发现
- ≥10包年吸烟者5年总生存率为82.3%(95%CI:76.0%-89.1%),低于<10包年者的93.6%(95%CI:89.7%-97.8%)。
- 按AJCC第八版临床分期分层,仅I期患者中<10包年吸烟者5年OS为98.7%(95%CI:96.3%-100.0%),显著优于≥10包年者的84.8%(95%CI:76.4%-94.1%)。
- 多变量分析中,调整AJCC第八版临床分期后,≥10包年吸烟与死亡风险增加相关(HR:2.52;95%CI:1.16-5.46)。
- 调整病理分期后,≥10包年吸烟与死亡风险增加相关(HR:5.21;95%CI:1.47-18.5)。
- 在临床和病理分期分析中,III期患者生存均差于I期,且吸烟在较低分期中影响更大。
临床怎么用
- 对HPV阳性口咽癌患者应详细采集吸烟史(包年数),以辅助预后评估。
- 在考虑降强度治疗试验时,需纳入吸烟状态作为分层或调整因素。
局限性
- 本研究为单中心回顾性队列研究,证据等级为2b。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prognostic significance of smoking in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) when considering American Joint Committee on Cancer eighth edition (AJCC-8) stage. STUDY DESIGN: Retrospective cohort study. METHODS: Three hundred seventeen HPV-positive OPSCC patients with known AJCC-8 stage and smoking status (<10 or ≥10 pack-years) seen at a tertiary center from 1997 to 2017 were studied. We used the Kaplan-Meier method to compare 5-year overall survival (OS) by smoking status and by clinical AJCC-8 stage and smoking status combined. Hazard ratios (HRs) were estimated with Cox proportional hazard regression for the independent effects of smoking and AJCC-8 stage. We also studied pathologic stage and estimated the combined effects of smoking and clinical stage. RESULTS: The ≥10 pack-years smokers had worse 5-year OS than <10 pack-years smokers (93.6%; 95% confidence interval (CI): 89.7-97.8 vs. 82.3%; 95% CI: 76.0%-89.1%). When stratified by AJCC-8 clinical stage, only stage I <10 pack-years smokers (98.7%; 95% CI: 96.3%-100.0%) had significantly better 5-year OS than their ≥10 pack-years (84.8%; 95% CI: 76.4%-94.1%) counterparts. In a multivariable analysis, ≥10 pack-years smoking was associated with increased hazard of death when adjusting for AJCC-8 clinical (HR: 2.52; 95% CI: 1.16-5.46) and pathologic (HR: 5.21; 95% CI: 1.47-18.5) stage. In both analyses, stage III patients demonstrated worse survival than stage I, and smoking had greater impact at lower stages. CONCLUSIONS: Smoking is a negative prognosticator in HPV-positive OPSCC and interacts with AJCC-8 clinical stage. It is important to understand the impact of smoking in HPV-positive disease when considering treatment plans and deintensification trials. LEVEL OF EVIDENCE: 2b Laryngoscope, 130: 1961-1966, 2020.
引用
- Chidambaram S, Nakken ER, Kennedy W, et al. Prognostic Significance of Smoking in Human Papillomavirus-Positive Oropharyngeal Cancer Under American Joint Committee on Cancer Eighth Edition Stage. Laryngoscope. 2020. PMID: 32293733. doi:10.1002/lary.28659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。